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Abstract
Background: Solitary fibrous tumors of the pleura (SFTP) are rare and their long-term outcome is difficult to predict,
as there are insufficient data which allow accurate characterization of the malignant variant. Thus the aim of this
study was to describe the outcome and possible determinants of malignant behavior of SFTPs.
Methods: Data were collected retrospectively from medical records of patients treated at the University Hospital
Zurich from 1992 to 2012. Kaplan-Meier and Cox regression analysis were performed to define disease-free survival
time (defined as survival without tumor-recurrence or tumor-related death) using the classical histo-morphological
criteria (tumor size, localization, pedunculation, tumor necrosis or hemorrhage, mitotic activity and nuclear
pleomorphism) and immunohistochemical parameters.
Results: 42 patients (20 males) with SFTP (median (IQR) age 62 (56–71) years) could be identified. SFTP were
associated with symptoms in 50% of all cases. Complete resection was achieved by video-assisted thoracic surgery
or thoracotomy in 20 and 22 patients, respectively. Three SFTP-related deaths (7.1%) and four tumor recurrences
(9.5%) were observed. Mean disease-free survival time was 136.2 (±13.1) months, and 2-, 5- and 10-year disease-free
survival was 91%, 84%, and 67%, respectively. Mean disease-free survival inversely correlated with the mean tumor
diameter, number of mitotic figures and proliferation rate (Ki-67 expression). Other criteria (tumor necrosis, atypical
localization, sessile tumor, and pleomorphism) were not statistically significant prognostic parameters.
Conclusions: Patients with large SFTP with a high mitotic index and high proliferation rate should be followed-up
closely and over a prolonged time period in order to recognize recurrence of the SFTP early and at a treatable
stage. Future research on this topic should focus on the prognostic role of immunohistochemistry including Ki-67
expression and molecular parameters.
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Background
Solitary fibrous tumors of the pleura (SFTP) account for
less than 5% of all pleural tumors and have a reported in-
cidence of 2.8 cases/100’000 persons per year [1,2]. Since
their first description in 1931, approximately 1000 cases
have been described in the literature. Historically, the
taxonomy of these tumors was heterogeneous. The terms
included “localized mesothelioma” or “submesothelial
fibroma” reflecting the disagreement concerning the
etiology and pathogenesis of these neoplasms [3]. More
recently, SFTP were shown to arise from the submesothe-
lial layer, as expression of vimentin and CD34 - both
markers of mesenchymal cells - was detected [4,5]. The
majority of these tumors follow a benign course with a
high cure rate [2,6]. However, features of malignancy are
found in 7-60% [6-8], and in such tumors a high recur-
rence rate and excess mortality have been reported [9]. In
addition, some benign SFTP may transform into the ma-
lignant variant, sometimes several years after complete
surgical resection [10].
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To date, there is insufficient information to predict the
biological behavior of these tumors which is partly re-
lated to very few data on immunohistochemical and mo-
lecular markers and limited long-term follow-up data in
SFTP [11-13]. Hence, there is a need to define para-
meters that characterize the malignant variant based on
clinico-pathological, immunohistochemical, or molecular
findings. The objective of this study was to describe the
clinicopathological presentation of SFTP and its impact
on the outcome.
Methods
Subjects and data
Between January 1, 1992 and December 31, 2012, all con-
secutive patients with histologically proven SFTP treated
at the University Hospital Zurich were included in the
present study. Data on demographics, the initial presen-
tation and surgical treatment were collected from me-
dical records. Follow-up data were collected from routine
postoperative surveillance examinations, which were
performed every six months for five years and yearly
thereafter with low-dose computed tomography, or from
contact with general practitioners. Written informed con-
sent was obtained from all patients or their relatives. The
study was approved by the Ethics committee of the
Canton of Zurich, Switzerland (KEK-ZH 2012–0279).
Outcomes und definition of malignancy
The primary variable of interest of the study was disease-
free survival time. Events were defined either as tumor-
related death, recurrence of the tumor or evidence of
metastases. Malignant SFTP were defined according to
the historical criteria proposed by Okike et al. [2] if one or
more of the following features were present: (1) high cel-
lularity, (2) high mitotic activity with more than four
mitotic figures per 10 high-power fields (HPF), and (3)
pleomorphism.
Possible predictors of outcome
In addition to the aforementioned three pathologic fea-
tures [2], possible predictors of outcome were clinico-
pathologic factors described by England et al. [6]: (a)
tumor size greater than 10 cm in diameter, (b) atypical
localization (SFTP attached to parietal pleura, fissure, or
mediastinum, or inverted into lung parenchyma), (c) sessile
or pedunculated tumor, (d) existence of necrosis or he-
morrhage, (e) more than four mitoses per 10 high-power
fields (HPF), and (f) nuclear pleomorphism (expressed as
increased nuclear grades). Furthermore, demographic (age,
gender, smoking status), clinical (symptoms, radiological
findings), and immunohistochemical variables (Ki-67,
Cytokeratin, Desmin, Vimentin, CD 34, CD 99, bcl-2
(B-cell lymphoma 2 protein), SMA (smooths muscle
antigen), and S-100) were investigated for their possible
predictive value on disease-free survival. Ki-67 is a nuclear
protein that is expressed in proliferating cells, and thus a
surrogate marker of the cellular proliferation rate. It is im-
munostained with MIB-1 according to standard protocols
(DAKO M7240, 1:20) using the Ventana automated
Benchmark staining system (MIB-1 labeling index).
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics for Windows, version 20.0 (IBM Corporation,
Armonk, NY). Data are reported as median ± interquartile
range (IQR), or mean ± standard deviation (SD), or per-
centages as appropriate. Differences between malignant
and benign SFTP were assessed using χ2 tests. Kaplan-
Meier analysis was used to estimate disease-free survival.
Univariate analysis by Cox regression analysis was per-
formed to evaluate the possible predictive value on
disease-free survival of the above mentioned covariates.
Variables with a p-value of less than 0.05 in the uni-
variate analysis were entered into the multiple regression
Table 1 Preoperative demographic, clinical and
radiological characteristics of SFTP
Characteristics N = 42
Demographics Male gender, N (%) 20 (47.6)
Age [years] 63.0 (55.7-71.0)
Current or history of smoking, N (%) 22 (52.4)
Pack years of smoking (py) 2.5 (0–21.2)
Symptoms No symptoms 21 (50.0)
Dyspnea 11 (26.2)
Cough 10 (23.8)
Chest pain 10 (23.8)
Constitutional symptoms
(night sweats, weight loss)
6 (14.3)
Digital clubbing 4 (9.5)
Symptomatic hypoglycemia 2 (4.7)
Laboratory
results
Hemoglobin [g/l] 137.0 (117.0-149.0)
Leucocytes count [× 109/l] 7.2 (5.8-8.7)
C-reactive protein [mg/l] 3.0 (2.0-14.0)
Blood glucose [mmol/l] 5.4 (5.1-6.3)
Radiology Extra-pulmonary mass 37 (88.1)
Inhomogeneous mass 17 (40.5)
Contact to pleura 37 (88.1)
Pleural effusion 5 (11.9)
Displacing other anatomical
structures
13 (31.0)
Invasion into other anatomical
structures
2 (4.8)
Focal calcification 5 (11.9)
Localization in lower lobes 22 (52.4)
Values are median (IQR) where applicable.
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Table 2 Histomorphological and immunohistochemical profile of SFTP
All (n = 42) Malignant (n = 18) Benign (n = 24) p-value*
Histomorphology
Atypical localization 2 (4.8) 1 (5.6) 1 (4.2) ns
Tumor size [cm] 6.2 (4.8-14.1)
Tumor size > 10 cm 19 (45.2) 12 (66.7) 7 (29.2) 0.002
Sessile tumor 11 (26.2) 7 (38.9) 4 (16.7) ns
Necrosis 19 11 (61.1) 7 (29.2) 0.024
Nr of mitoses per 10 HPF 4.1 (1.0-7.25)
> 10 mitoses per 10 HPF 14 (33.3) 13 (72.2) 0 (0) 0.022
Pleomorphism 8 (19.0) 6 (33.3) 2 (8.3) 0.03
Immunohistochemistry
Ki-67 (proliferation rate)** 5 (1–7) 13.3 3.2 0.01
Ki-67 > 12%** 3/27 (11.1) 3 (30) 0 0.02
Vimentin 16/18 (88.9) 8 (88.9) 8 (88.9) ns
Cytokeratin 1/19 (5.3) 0 (0) 1 (10.0) ns
Desmin 4/16 (25.0) 3 (33.3) 1 (14.3) ns
SMA 1/18 (5.6) 1 (12.5) 0 (0) ns
CD 34 35/36 (97.2) 16 (94.1) 19 (100) ns
CD 99 14/18 (77.8) 5 (55.6) 9 (100.0) ns
bcl-2 21/22 (95.5) 8 (88.9) 13 (100.0) ns
S-100 0/23 (0) 0 (0) 0 (0) ns
Values are N (%) or median (IQR) where applicable.
*Chi-quare test; ns, not significant; HPF, high-power field; SMA, smooth muscle antigen; bcl-2, B-cell lymphoma 2 protein; **Proliferations rate is determined by
Ki-67 expression (MIB-1 labeling index).
Figure 1 Disease-free survival in solitary fibrous tumors of the pleura. Mean disease-free survival was 136.2 (±13.1) months, and 2-, 5- and
10-year disease-free survival was 91%, 84%, and 67%, respectively.
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model. For statistical significant variables, the hazard ratio
(HR) with a 95% confidence interval (CI) was calculated.
P-values of all outcomes were two-sided; a value less than
0.05 was considered to indicate statistical significance.
Results and discussion
Demographic and clinical data
Between 1992 and 2012, a total of 42 patients (20 males)
with histologically proven SFTP were treated at the
University Hospital Zurich. Demographic, clinical and
radiological data are summarized in Table 1.
Therapy and pathology
SFTP’s were resected by a wedge resection (75.6%) fol-
lowed by lobectomy (17.1%) or pneumonectomy (7.3%)
in cases where the tumor was extensive and adherent
to the lung. In 20 patients (47.6%), the operation was
performed by thoracoscopy. R0-resection (tumor-free
margins) was achieved in all patients irrespective of the
surgical method. Perioperative complications were seen in
seven patients (16.7%) including prolonged air leak (n = 3),
infection (n = 2), bleeding (n = 1), and intercostal neuralgia
(n = 1). The mean length of hospital stay was 6 (IQR 4–9)
days, and perioperative mortality was 0%.
Eighteen SFTP (42.9%) were classified as malignant.
The histomorphological and immunohistochemical pro-
file of SFTP are summarized in Table 2.
Disease-free survival
Mean disease-free survival was 136.2 (±13.1) months,
and 2-, 5- and 10-year disease-free survival was 91%,
84%, and 67%, respectively (Figure 1). During the me-
dian follow-up time of 39 (14–78) months, the endpoint
(recurrence or SFTP-related death) was reached in five
patients (11.9%). Recurrence of SFTP was found in four
patients (9.5%), and SFTP-related mortality was 7.1%.
Univariate analysis
In univariate Cox regression analysis, large tumor size
(HR 1.24, 95% CI 1.04-1.47, p = 0.015), high mitotic rate
Table 3 Investigated variables with a possible impact on the outcome of patients with solitary fibrous tumors of
the pleura
Variable HR CI p-value*
Univariate analysis
Gender 0.54 0.89-3.26 ns
Age 1.13 0.91-1.30 ns
History of smoking 2.26 0.29-2.35 ns
Symptomatic SFTP 1.19 0.20-7.14 ns
Inhomogeneous appearance on CT 4.69 0.48-45.52 ns
Sessile SFTP 3.90 0.43-35.04 ns
Necrosis or hemorrhage 0.14 0.02-1.31 ns
Atypical localization 0.04 0.03-4.3 ns
Malignant SFTP according to Okike classification [2] 0.21 0.02-2.00 ns
Pleomorphism 0.45 0.07-2.74 ns
Desmin 2.35 0.43-5.34 ns
Vimentin 3.65 0.33-40.32 ns
CD 34 1.0 0.8-2.2 ns
CD 99 4.84 0.44-53.81 ns
Bcl-2 5.32 0.87-7.34 ns
SMA 2.29 0.03-8.54 ns
Tumor diameter≥ 10 cm 1.24 1.04-1.47 0.015**
≥ 10 mitotic figures/10 HPF 1.33 1.08-1.63 0.008**
Proliferation rate≥ 12%*** 1.09 1.02-1.16 0.015**
Multivariate analysis
Tumor diameter≥ 10 cm 12.45 0.28-5578.61 ns
≥ 10 mitotic figures/10 HPF 2.29 0.29-18.12 ns
Proliferation rate≥ 12%*** 1.53 0.35-6.64 ns
*Cox regression analysis; **Variables with a p-value ≤ 0.05 were entered into the multivariate analysis; ***Determined by Ki-67 expression (MIB-1 labeling index);
HR, hazard ratio; CI, confidence interval; CT, computed tomography; ns, not significant; HPF, high-power field, SFTP, solitary fibrous tumor of the pleura; SMA,
smooth muscle antigen; bcl-2, B-cell lymphoma 2 protein.
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(HR 1.33, 95% CI 1.08-1.63, p = 0.008), and high prolife-
ration rate (HR 1.09, 95% CI 1.02-1.16, p = 0.015) were
significantly associated with impaired disease-free sur-
vival (Table 3). All patients with high proliferation rate
also had a mitotic rate over 10/HPF. Comparative disease-
free survival curves in SFTP with and without tumor
diameter greater than 10 cm, number of mitotic figures
over 10 per 10 HPF, and proliferation rate (Ki-67, MIB-1)
greater than 12% are displayed in Figures 2, 3 and 4.
Hence, from the clinicopathologic features proposed by
England et al. [6], only tumor size and the number of
mitoses showed a statistically significant association with
disease-free survival, whereas atypical localization, sessile
or pedunculated tumor, existence of necrosis or hemor-
rhage, and pleomorphism were not predictive for disease-
free survival. Furthermore, the classification in malignant
and benign variants according to the pathologic features
published by Okike et al. [2] showed no statistically signifi-
cant association with disease-free survival (Table 3).
Multivariate analysis
In multiple regression analysis, none of the features, which
were significantly associated with disease-free survival in
the univariate analysis, remained statistically significantly
associated with disease-free survival after correction for
covariates.
Discussion
In univariate analysis, impaired outcome in patients with
histologically proven SFTP inversely correlated with
mean tumor diameter, number of mitotic figures per 10
high-power fields, and proliferation rate (measured with
Ki-67, a nuclear protein that is expressed in proliferating
cells and immunostained with MIB-1). However, these
associations did not remain significant in the multivari-
ate analysis, possibly due to the limited number of in-
cluded cases. Beyond complete resection of SFTP, which
has been shown to be a major prognostic indicator by
several authors [2,6,14-16], and was achieved in all our
cases, several histomorphologic, immunohistochemical,
or molecular features may correlate with prognosis. How-
ever, the evidence concerning factors predicting a worse
outcome is conflicting throughout the literature. Histo-
morphologic characteristics apparently predicting aggres-
sive behavior (including local recurrence, metastases or
SFTP-related death) were first described by England et al.
[6] and included tumor size greater than 10 cm in dia-
meter, atypical localization, sessile tumor, existence of
Figure 2 Disease-free survival grouped by tumor diameter. Mean disease-free survival time in solitary fibrous tumors of the pleura with
tumor diameter greater than 10 cm was 66.7 (±10.4) compared to 153.6 (±12.9) months in smaller tumors.
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necrosis or hemorrhage, more than four mitoses per
10 high-power fields (HPF), and nuclear pleomorphism.
However, none of these factors seems to accurately predict
an impaired outcome, as 59% of SFTP may display at least
one of the above mentioned features, whereas mortality
and recurrence have only been observed in 10% and 18%
of all cases, respectively [11].
More recently, de Perrot et al. proposed a staging sys-
tem mainly based on the sessile morphology of SFTP
and on the above mentioned characteristics in order to
identify SFTP at high risk of aggressive behavior [17]. In
2008, this modified staging system was evaluated by
Schirosi et al. [11] who were able to show a significant
correlation with overall and disease-free survival. How-
ever, in the multivariate analysis of the latter study, the
authors found that only tumor necrosis and high p53 ex-
pression were parameters significantly associated with
overall and disease-free survival [11].
So far only a few immunohistochemical and molecular
parameters with a possible impact on prognosis in SFTP
have been investigated. High p53 expression has pre-
viously been shown to correlate with malignancy by
others [18,19]. Also, loss of CD34 expression and cyto-
keratin (CK) positivity was considered to correlate with
unfavorable outcome in SFTP [18,20-22]. Recently, the
prognostic value of CD34 negativity was confirmed in a
large retrospective study conducted in 157 patients with
SFTP [23]. The same authors confirmed that sessile mor-
phology was a significant risk factor for recurrence, but
interestingly tumor size was not associated with the out-
come [23]. Other previously mentioned histomorphologi-
cal features were not considered in the latter study [23].
Unexpectedly the authors found no significant difference
of survival between patients with malignant and those
with benign SFTP, whereas recurrence was more common
in patients with malignant variants [23].
In contrast to some previous studies [6,17,23], we did
not find that sessile configuration of SFTP was signi-
ficantly associated with the outcome. Similarly, Lococo
et al. did not find a significant association between ses-
sile morphology and outcome in SFTP [16].
In the current study, prognosis was not affected by pa-
tient’s age, the site (visceral or parietal pleura) or by the
existence of pleural effusion. Also, in univariate analysis,
characterization as malignant or benign tumors accord-
ing to the criteria by Okike et al. [2] was not significantly
predictive for disease-free survival. From the clinicopatho-
logic features described by England et al. [6], only tumor
Figure 3 Disease-free survival grouped by number of mitotic figures. Mean disease-free survival time in solitary fibrous tumors of the pleura
with a number of mitotic figures over 10 per 10 high-power fields was 44.6 (±17.9) compared to 147.4 (±12.8) months in tumors with less mitoses.
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size and mitotic rate were significantly correlated with the
outcome, which confirms previous findings [6,12,17]. In
the current study, high proliferation rate, assessed by
Ki-67, a nuclear protein that is expressed in proliferating
cells, and immunostained with MIB-1, significantly corre-
lated with adverse outcome. Ki-67 expression was previ-
ously considered as prognostic parameter in other studies
including relatively small series consisting of up to 18 sub-
jects [24-26]. However, despite markers of an increased
cell proliferation have been shown to correlate with worse
prognosis in patients with other tumors, such as breast
[27,28] and bladder cancer [29], the role of Ki-67 immu-
nostaining has not been systematically investigated in
SFTP so far. Recently, a cut off level of a proliferation rate
of 12% (Ki-67) was proposed to indicate benign and ma-
lignant lesions [30]. However, assessment of Ki-67 may
suffer from inter- and intra-observer variability, since
there is an area of uncertainty whether and how MIB-1 la-
beling index should be counted or estimated [31].
Regarding the role of other immunohistochemical
staining methods for predicting prognosis, we could not
confirm the findings of others concerning CD34 nega-
tivity [18,23]. In our study, we were not able to identify
any immunohistochemical marker other than Ki-67 (in-
cluding positivity for Vimentin, CD99, or bcl-2, and
negativity for CD34, SMA, and S-100) to correlate with
disease-free survival. However, the role of immunohisto-
chemical (particularly Ki-67 expression) and distinct mo-
lecular techniques (including p16 expression) have yet to
be determined in a future study. Furthermore, the prog-
nostic role of rearrangement of chromosome 8 according
to some case reports [32,33] and the role of microRNAs
has to be investigated.
The present study has some inherent limitations mainly
due to the retrospective design. The sample size in
our study is relatively small, which might impair the
interpretability of the multivariate analysis and the overall-
survival analysis. For this reason we have chosen to dis-
play the disease-free survival only. However, we feel
that the findings of our study merit attention, because
proliferation rate in SFTP has been considered as a
possible prognostic parameter in very few and small
case series only. Noteworthy, our series is the largest
investigating the proliferation rate measured with Ki-
67 immunostaining and its impact on outcome in
SFTP.
Figure 4 Disease-free survival grouped by proliferation rate (Ki-67). Mean disease-free survival time in solitary fibrous tumors of the pleura
with a proliferation rate (Ki-67 expression, MIB-1 labeling index) greater than 12% was 15.0 (±9.0) compared to 110.2 (±6.1) months in those with
less proliferation rate.
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Conclusions
Tumor-related mortality, recurrence or metastases are dif-
ficult to predict in SFTP solely based on demographic,
histo-pathological or clinical parameters. High mitotic rate,
large tumor size, and high proliferation rate seem to be as-
sociated with adverse outcome. Hence, to date the defin-
ition of malignant SFTP should refer to these parameters.
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